Collectively, these findings not only demonstrate that 90K is a meaningful biomarker for glioma malignancy and prognosis, but provide a novel strategy based on 90K-apoptotic tumor cell pulsed DC targeted vaccine for cancer immunotherapies. Here, LGALS3BP is linked to cancer.